Senores Pharmaceuticals Limited (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, USA (SPI), has signed an agreement to acquire two USFDA-approved Abbreviated New Drug Applications (ANDAs) from Teva Pharmaceuticals USA, Inc.

The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA (MAT December 2024, IQVIA) and about USD 120 million (MAT June 2025, Symphony).

The acquisition will be funded through proceeds from SPL’s Initial Public Offer, as stated in the Red Herring Prospectus.